Cargando…

PD-L1 Testing in Gastric Cancer by the Combined Positive Score of the 22C3 PharmDx and SP263 Assay with Clinically Relevant Cut-offs

PURPOSE: We provide a comparison between 22C3 pharmDx and SP263 assay, for evaluating programmed death ligand 1 (PD-L1) expression in advanced gastric cancer (GC) patients. MATERIALS AND METHODS: The PD-L1 immunohistochemistry by 22C3 pharmDx and SP263 assays was performed in the center of the tumor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Park, Yujun, Koh, Jiwon, Na, Hee Young, Kwak, Yoonjin, Lee, Keun-Wook, Ahn, Sang-Hoon, Park, Do Joong, Kim, Hyung-Ho, Lee, Hye Seung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Cancer Association 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373862/ https://www.ncbi.nlm.nih.gov/pubmed/32019283 http://dx.doi.org/10.4143/crt.2019.718

Ejemplares similares

Intrapatient Tumor Heterogeneity in IHC Interpretation Using PD-L1 IHC 22C3 pharmDx
por: Kalpakoff, Megan, et al.
Publicado: (2021)

Equivalence of laboratory-developed test and PD-L1 IHC 22C3 pharmDx across all combined positive score indications
por: Vainer, Gilad, et al.
Publicado: (2023)

Evaluating programmed death‐ligand 1 (PD‐L1) in head and neck squamous cell carcinoma: concordance between the 22C3 PharmDx assay and the SP263 assay on whole sections from a multicentre study
por: Cerbelli, Bruna, et al.
Publicado: (2021)

Analysis of real-world PD-L1 IHC 28-8 and 22C3 pharmDx assay utilisation, turnaround times and analytical concordance across multiple tumour types
por: Krigsfeld, Gabriel S, et al.
Publicado: (2020)

Population-based estimate for the correlation of the Oncotype Dx Breast Recurrence Score® result and Ki-67 IHC MIB-1 pharmDx in HR+, HER2−, node-positive early breast cancer
por: Crager, Michael, et al.
Publicado: (2022)

An Analytical Comparison of Dako 28-8 PharmDx Assay and an E1L3N Laboratory-Developed Test in the Immunohistochemical Detection of Programmed Death-Ligand 1
por: Cogswell, John, et al.
Publicado: (2016)

Comparison of HercepTest™ mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2/neu (4B5) in breast cancer: correlation with HER2 amplification and HER2 low status
por: Rüschoff, Josef, et al.
Publicado: (2022)

Expression of the immune checkpoint receptors PD-1, LAG3, and TIM3 in the immune context of stage II and III gastric cancer by using single and chromogenic multiplex immunohistochemistry
por: Park, Yujun, et al.
Publicado: (2021)

Differential prognostic impact of CD8(+) T cells based on human leucocyte antigen I and PD-L1 expression in microsatellite-unstable gastric cancer
por: Kwak, Yoonjin, et al.
Publicado: (2020)

Prognostic significance of natural killer cell-associated markers in gastric cancer: quantitative analysis using multiplex immunohistochemistry
por: Na, Hee Young, et al.
Publicado: (2021)

CT‐guided transthoracic needle biopsy for evaluation of PD‐L1 expression: Comparison of 22C3 and SP263 assays
por: Beck, Kyongmin S., et al.
Publicado: (2019)

Fat pharms.
por: Ma, M
Publicado: (1996)

The technology of pharming
por: Rehbinder, Eckard, et al.
Publicado: (2009)

External quality assessment demonstrates that PD‐L1 22C3 and SP263 assays are systematically different
por: Dodson, Andrew, et al.
Publicado: (2019)

Prediction of TP53 mutations by p53 immunohistochemistry and their prognostic significance in gastric cancer
por: Hwang, Hye Jung, et al.
Publicado: (2020)

Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients
por: Koh, Jiwon, et al.
Publicado: (2017)

The Evolution of PharmVar
por: Gaedigk, Andrea, et al.
Publicado: (2018)

Legal problems of pharming
por: Rehbinder, Eckard, et al.
Publicado: (2009)

Comprehensive Comparison of 22C3 and SP263 PD-L1 Expression in Non-Small-Cell Lung Cancer Using Routine Clinical and Conditioned Archives
por: Kim, Sue Youn, et al.
Publicado: (2022)

PD-L1 expression evaluated by 22C3 antibody is a better prognostic marker than SP142/SP263 antibodies in breast cancer patients after resection
por: Cha, Yoon Jin, et al.
Publicado: (2021)

ECOLOGY AND WILDLIFE: Pharmed Fish
por: Betts, Kellyn S.
Publicado: (2009)

High-Throughput Multiplex Immunohistochemical Imaging of the Tumor and Its Microenvironment
por: Koh, Jiwon, et al.
Publicado: (2020)

Concordance of Programmed Death-Ligand 1 Expression between SP142 and 22C3/SP263 Assays in Triple-Negative Breast Cancer
por: Lee, Seung Eun, et al.
Publicado: (2020)

PharmGED: Pharmacogenetic Effect Database
por: Zheng, C. J., et al.
Publicado: (2007)

Cell Engineering and Molecular Pharming for Biopharmaceuticals
por: Abdullah, M.A, et al.
Publicado: (2008)

Introduction of APCs in J. Young Pharm.
por: Mueen, Ahmed KK
Publicado: (2012)

My Vision: J Young Pharm
por: Parasuraman, S
Publicado: (2012)

Health Tract, No. 263: Experimenting
Publicado: (1867)

263 Clinical Features of Drug Rash with Eosinophilia and Systemic Symptoms Syndrome Caused by Antituberculous Medications
por: Kim, Sang-Ha, et al.
Publicado: (2012)

Cut-Off Values of Visceral Fat Area and Waist-to-Height Ratio: Diagnostic Criteria for Obesity-Related Disorders in Korean Children and Adolescents
por: Lee, Kang-Kon, et al.
Publicado: (2012)

Cut-off value for exercise-induced bronchoconstriction based on the features of the airway obstruction
por: Kang, Noeul, et al.
Publicado: (2022)

A Novel Loss-of-Function Variant in Transmembrane Protein 263 (TMEM263) of Autosomal Dwarfism in Chicken
por: Wu, Zhou, et al.
Publicado: (2018)

The Cut-off Value of Blood Mercury Concentration in Relation to Insulin Resistance
por: Lee, Seok-Hoon, et al.
Publicado: (2017)

Pharm D: A new concept in India
por: Deshpande, Prasanna R., et al.
Publicado: (2012)

Pharmacogenomics Clinical Annotation Tool (PharmCAT)
por: Sangkuhl, Katrin, et al.
Publicado: (2019)

Preventing hospital admissions by reviewing medication (PHARM) in primary care: design of the cluster randomised, controlled, multi-centre PHARM-study
por: Leendertse, Anne J, et al.
Publicado: (2011)

DX centers
por: Munoz Merino, Elias
Publicado: (1994)

Cut-off values for diagnosis of G6PD deficiency by flow cytometry in Thai population
por: Thedsawad, Anchalee, et al.
Publicado: (2022)

Immunoscore encompassing CD3+ and CD8+ T cell densities in distant metastasis is a robust prognostic marker for advanced colorectal cancer
por: Kwak, Yoonjin, et al.
Publicado: (2016)

AIMP2-DX2 provides therapeutic interface to control KRAS-driven tumorigenesis
por: Kim, Dae Gyu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_esqsl0k2re7vctdv0he0toul2d